Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
#44
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Aim(s): To evaluate the impact of SSA use on health-related quality of life (HRQL) in patients with NETs.
Materials and methods: Patients with NETs were invited via e-mail to participate in an online anonymous survey. The survey consisted of demographics, disease-related questions and standardized measures of HRQL (RAND-36 and PROMIS-29). Within the subgroup of patients with carcinoid syndrome, RAND-36 scores were compared between patients who reported treatment with an SSA in the past month versus those who did not using two-sample t-tests. Score differences of 2.5 - 5.0 points are generally regarded as clinically meaningful. Lower scores indicate worse HRQL.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author:
Authors: Yao J, Beaumont J, Choi S, Cella D, Liu Z,
Keywords: neuroendocrine tumor, health-related quality of life, somatostatin analogue, carcinoid syndrome,
To read the full abstract, please log into your ENETS Member account.